2nd Quarter - Report

TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC

Firm
Client
Income
—
Expenses
$160,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 6: 21st Century Cures/Innovation Act

LobbyistCovered position, as disclosed
SHELLEY STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); CMMI Proposed Part B Payment Model

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
SHELLEY STEWART —
DEBORAH LYNN WALTER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2404 (114th)

Budget/Appropriations BUD

Vial Size/Appropriations

LobbyistCovered position, as disclosed
LAURA ELIZABETH CLINE —
SHELLEY STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Moonshoot Initiative

LobbyistCovered position, as disclosed
SHELLEY STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.